Silo Pharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table shows the fees for services provided by Salberg & Company, P.A. for the years ended December 31, 2024 and 2023.
| 2024 | 2023 | |
|---|---|---|
| Audit Fees | $72,000 | $64,000 |
| Audit Related Fees | 12,000 | – |
| Tax Fees | - | – |
| All Other Fees | - | – |
| Total | $84,000 | $64,000 |
Audit Fees: Audit fees consist of fees billed for professional services performed by Salberg & Company, P.A. for the audit of our annual consolidated financial statements, and the review of interim consolidated financial statements.
Audit-Related Fees: Audit-related fees may consist of fees billed by our independent registered public accounting firm for audit-related consulting services related to registration statements.
Tax Fees: Tax fees may consist of fees for professional services, including tax compliance. There were no such fees paid by the Company to Salberg & Company, P.A. in the fiscal years ended December 31, 2024 and 2023.
**All Other Fees:There were no such fees incurred by the Company in the fiscal years ended December 31, 2024 and 2023. **
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.